Lifecore Biomedical, Inc. (NASDAQ:LFCR) Major Shareholder Sells $321,256.94 in Stock

Lifecore Biomedical, Inc. (NASDAQ:LFCR - Get Free Report) major shareholder Aron R. English sold 45,698 shares of the company's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $7.03, for a total transaction of $321,256.94. Following the completion of the sale, the insider now owns 1,662,574 shares in the company, valued at approximately $11,687,895.22. This trade represents a 2.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.

Lifecore Biomedical Stock Performance

NASDAQ LFCR traded up $0.18 during trading hours on Friday, reaching $6.89. The company's stock had a trading volume of 183,659 shares, compared to its average volume of 234,682. The company has a current ratio of 2.32, a quick ratio of 1.21 and a debt-to-equity ratio of 9.21. The business has a 50-day simple moving average of $6.48 and a 200 day simple moving average of $6.54. Lifecore Biomedical, Inc. has a 52 week low of $3.68 and a 52 week high of $7.99. The stock has a market cap of $255.10 million, a PE ratio of -12.30 and a beta of 0.65.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last announced its quarterly earnings results on Thursday, April 3rd. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. The firm had revenue of $35.15 million during the quarter, compared to analyst estimates of $33.23 million. Equities research analysts predict that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

Institutional Trading of Lifecore Biomedical

A number of large investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Lifecore Biomedical by 14.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company's stock worth $104,000 after purchasing an additional 1,886 shares during the period. Bridgeway Capital Management LLC boosted its stake in Lifecore Biomedical by 2.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 78,800 shares of the company's stock worth $585,000 after purchasing an additional 1,900 shares during the period. Wells Fargo & Company MN boosted its stake in Lifecore Biomedical by 29.0% in the 4th quarter. Wells Fargo & Company MN now owns 13,381 shares of the company's stock worth $99,000 after purchasing an additional 3,012 shares during the period. Bank of New York Mellon Corp boosted its stake in Lifecore Biomedical by 3.8% in the 1st quarter. Bank of New York Mellon Corp now owns 83,663 shares of the company's stock worth $589,000 after purchasing an additional 3,091 shares during the period. Finally, GAMMA Investing LLC boosted its stake in Lifecore Biomedical by 1,839.7% in the 1st quarter. GAMMA Investing LLC now owns 3,569 shares of the company's stock worth $25,000 after purchasing an additional 3,385 shares during the period. 83.36% of the stock is currently owned by institutional investors.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.